MediKidz' haemophilia comic

Novo Nordisk sponsors haemophilia comic

pharmafile | October 7, 2011 | News story | Medical Communications Novo Nordisk, haemophilia, medical communications news 

Novo Nordisk is sponsoring an educational comic about haemophilia for young sufferers of the blood disorder in the UK.

It features the MediKidz, a group of five superheroes from Mediland – a planet shaped like the human body.

The characters are intended to span cultures and appeal across the eight to 15 year old age group to engage with a young audience.

Novo Nordisk’s director of BioPharm Esben Bruun Mortensen said: “The comics are a useful medical educational tool and of genuine value to doctors in their clinical practice. The biggest advantage is to patients as education improves compliance with treatment.”

Produced by medical education publisher MediKidz, the comic will be made available to clinicians in order to help the hundreds of children with haemophilia and rare blood disorders to better understand their condition

Dr Kate Hersov, co-founder of MediKidz, said: “MediKidz is a teaching tool concept adaptable for any medical therapy and provides a unique way of teaching. The company focuses on children and was founded by doctors to explain medical topics in a way they can understand.”

Novo Nordisk currently markets the NovoSeven drug for haemophilia and has a new bleeding disorder agent, NN7415, in Phase I trials for the condition.

Dominic Tyer

Related Content

anirudh-djo3injpaoe-unsplash_3

Pfizer’s Beqvez approved by FDA for haemophilia B treatment

Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene …

CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …

Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment

Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk …

Latest content